ID: ALA5181502

Max Phase: Preclinical

Molecular Formula: C23H25F3N2O2

Molecular Weight: 418.46

Representations

Canonical SMILES:  O=C1OC(CCCN2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)c2ccccc21

Standard InChI:  InChI=1S/C23H25F3N2O2/c24-23(25,26)18-9-7-17(8-10-18)16-28-14-12-27(13-15-28)11-3-6-21-19-4-1-2-5-20(19)22(29)30-21/h1-2,4-5,7-10,21H,3,6,11-16H2

Standard InChI Key:  JJUSXWIHZMANLG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 418.46

Molecular Weight (Monoisotopic): 418.1868

AlogP: 4.51

#Rotatable Bonds: 6

Polar Surface Area: 32.78

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.88

CX Basic pKa: 8.07

CX LogP: 4.63

CX LogD: 3.88

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.65

Np Likeness Score: -0.57

References

1. Xu Q, Hu M, Li J, Ma X, Chu Z, Zhu Q, Zhang Y, Zhu P, Huang Y, He G..  (2022)  Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.,  227  [PMID:34710748] [10.1016/j.ejmech.2021.113876]

2. Xu Q, Hu M, Li J, Ma X, Chu Z, Zhu Q, Zhang Y, Zhu P, Huang Y, He G..  (2022)  Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.,  227  [PMID:34710748] [10.1016/j.ejmech.2021.113876]

3. Xu Q, Hu M, Li J, Ma X, Chu Z, Zhu Q, Zhang Y, Zhu P, Huang Y, He G..  (2022)  Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.,  227  [PMID:34710748] [10.1016/j.ejmech.2021.113876]

Source

Source(1):

• Scientific Literature